Eligibility check
Answer a few questions and we compare your situation with the published access and reimbursement criteria in your country — then show you exactly which listed providers fit. It takes about two minutes. The check runs in your browser, and nothing you enter is sent anywhere unless you choose to submit an enquiry.
Check your eligibility across Europe — in about 2 minutes
Answer a few questions and we’ll compare your situation with the published access and reimbursement criteria in your country. This is a self-assessment, not medical advice.
Informational self-assessment only. This eligibility check compares your answers with published access and reimbursement criteria. It is not a medical diagnosis, medical advice, or a treatment decision, and it cannot determine whether treatment is right or safe for you. Always consult a licensed clinician. In a crisis, contact local emergency services or a crisis line immediately.
Screening logic and self-checks medically reviewed by Arielle Tandowski, MPH — 3 August 2026.
What we check against
- GermanyPublished reimbursement practice centres on a severe, treatment-resistant depressive episode; “adequate” antidepressant treatments mean a sufficient dose taken for several weeks, and the route differs for statutory (GKV) and private (PKV) insurance.
- FrancePublished French reimbursement criteria apply to adults under 65, after at least 2 antidepressants from 2 different classes have failed to bring sufficient improvement; treatment is organised through a hospital — the standard access route in France.
- SpainPublished Spanish criteria cover adults aged 18–74, after at least 3 treatment strategies have failed, including at least one augmentation strategy (adding a second medicine to an antidepressant).
- NetherlandsDutch criteria follow the depression treatment algorithm — usually 3 or more adequate treatment steps including an augmentation step, then referral to a specialised esketamine centre (ENC-NL network).
- PolandDrug programme B.147 requires depression documented as treatment-resistant by a clinician, antidepressants failed at adequate dose and duration, and NFZ (National Health Fund) coverage.
- SwitzerlandThe Swiss limitation requires both at least 2 antidepressants and at least 1 augmentation attempt without sufficient improvement, an illness rated as severe (e.g. a CGI-S score of 5 or higher), treatment at a BAG-designated centre, and insurer pre-approval of cost coverage.
- United KingdomNICE has not recommended esketamine (Spravato®) for routine NHS use, so NHS reimbursement is generally not available; access runs mainly through private, self-pay clinics regulated by the CQC, typically £300–£800 per session.
This is an informational self-assessment, not medical advice and not a clinical screening. It only mirrors criteria that regulators, payers, and clinics publish; the actual eligibility decision is always made by a treating clinician, and every provider runs its own pre-screening before treatment.
“This screener is a useful tool for those seeking alternative mental health treatments (i.e., esketamine, ketamine, and clinical trials) across Europe and the UK. It navigates complex regulations and reimbursement criteria to provide a simple summary of country-specific eligibility and directs users to potential providers if found eligible. It’s important to keep in mind that this self-assessment is not a diagnostic tool, but a starting point for understanding your options. Although the published criteria describe a typical candidate, certain clinics (especially private ones) may have different eligibility standards.” — Arielle Tandowski, MPH, reviewer
Before you speak to a clinician
A validated self-screener is not a diagnosis, but it helps you describe your symptoms in the language clinicians use. Each maps to a condition psychedelic medicine is used or studied for: depression (PHQ-9), anxiety (GAD-7), PTSD (PCL-5-based) and alcohol use (AUDIT) — the last because ketamine programmes for alcohol relapse and psilocybin research in alcohol-use disorder are part of the field.
“The PHQ-2 and GAD-2 are well-validated, ultra-abbreviated screeners (each using the first two items of the full PHQ-9 and GAD-7 screening tools). They are designed to quickly flag potential depression and anxiety symptoms. A positive result is not a diagnosis, but rather a starting point for further discussion and exploration with a clinician. Together, they address two of the most common mental health conditions, depression and anxiety.” — Arielle Tandowski, MPH, reviewer